Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CORZIDE vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of a beta-adrenergic receptor antagonist (nadolol) and a thiazide diuretic (bendroflumethiazide). Nadolol non-selectively blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Bendroflumethiazide inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension
Hypertension
Oral: 1 tablet daily containing nadolol 40 mg and bendroflumethiazide 5 mg. May increase to 2 tablets daily if needed.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Nadolol: 14-24 hours (prolonged in renal impairment up to 45 hours); bendroflumethiazide: 8-9 hours (may be prolonged in renal dysfunction).
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Nadolol: not extensively metabolized, excreted unchanged in urine. Bendroflumethiazide: minimally metabolized, excreted unchanged in urine.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Nadolol: ~73% excreted unchanged in urine via glomerular filtration; bendroflumethiazide: ~30% excreted unchanged in urine, remainder as metabolites via renal and biliary routes.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Nadolol: <30% bound to albumin; bendroflumethiazide: ~94% bound to albumin.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Nadolol: 1.9-2.5 L/kg (low, consistent with hydrophilic nature); bendroflumethiazide: not well characterized but estimated ~0.5-1 L/kg (small Vd due to high protein binding).
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Nadolol: ~30-40% (variable, first-pass metabolism minimal); bendroflumethiazide: bioavailability ~65% (oral).
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
GFR 30-50 m L/min: administer every 24 hours; GFR 10-29 m L/min: administer every 24-36 hours; GFR <10 m L/min: administer every 48 hours.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh Class B or C: use with caution; consider dose reduction or increased monitoring due to reduced clearance.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Not established; avoid use in children.
Start at lower dose (e.g., 1 tablet containing nadolol 20 mg and bendroflumethiazide 2.5 mg) and titrate slowly; monitor renal function and electrolytes.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None
None
Bronchospasm in patients with asthma/COPD,Heart failure exacerbation,Peripheral vascular disease worsening,Abrupt withdrawal may cause angina or MI,Masking of hypoglycemia in diabetics,Electrolyte disturbances (hypokalemia, hyponatremia),Increased BUN and serum creatinine,Orthostatic hypotension,Systemic lupus erythematosus exacerbation
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Bronchial asthma,Sinus bradycardia,Heart block greater than first degree,Cardiogenic shock,Uncompensated heart failure,Anuria,Hypersensitivity to thiazides or sulfonamides
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid potassium-rich foods (bananas, oranges, spinach, potatoes) in excess unless directed by a physician, as thiazides may cause hypokalemia, but monitoring is needed. Alcohol may potentiate hypotensive effects. Grapefruit juice may increase nadolol levels; avoid concurrent intake.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
CORZIDE (nadolol/bendroflumethiazide) is associated with fetal risk. First trimester: Potential teratogenic effects including hypospadias and neural tube defects with bendroflumethiazide; β-blocker use may increase risk of intrauterine growth restriction. Second trimester: Continued risk of placental insufficiency. Third trimester: Neonatal bradycardia, hypoglycemia, hypotension, and respiratory depression due to nadolol; electrolyte disturbances and volume depletion from bendroflumethiazide.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Nadolol is excreted into breast milk with a relative infant dose of approximately 2-5% of maternal weight-adjusted dose; M/P ratio not well defined. Bendroflumethiazide also appears in breast milk. Consider risk of infant bradycardia, hypotension, and electrolyte disturbances. Avoid use or monitor infant for adverse effects.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
No established dose adjustment guidelines. Consider reducing nadolol dose due to increased plasma volume and clearance in pregnancy. Bendroflumethiazide typically avoided in pregnancy; if used, monitor for volume depletion and electrolyte imbalance, and consider dose reduction. Clinical judgment required.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
Corzide (bendroflumethiazide/nadolol) combines a thiazide diuretic and a non-selective beta-blocker. Monitor for bradycardia, hypotension, hypokalemia, and hyperglycemia. Avoid abrupt withdrawal due to beta-blocker rebound. Use cautiously in asthma, COPD, diabetes, and peripheral vascular disease. Dosage adjustments needed in renal impairment.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not stop taking this medication suddenly; abrupt cessation can cause chest pain or heart attack.,Avoid alcohol, which can increase dizziness and drowsiness.,Report symptoms of low potassium (muscle cramps, weakness) or slow heart rate (dizziness, fainting).,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Use sunscreen and protective clothing as this medication may increase sensitivity to sunlight.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CORZIDE vs ALDORIL 25, answered by our medical review team.
CORZIDE is a Antihypertensive combination that works by Combination of a beta-adrenergic receptor antagonist (nadolol) and a thiazide diuretic (bendroflumethiazide). Nadolol non-selectively blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Bendroflumethiazide inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CORZIDE and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CORZIDE is: Oral: 1 tablet daily containing nadolol 40 mg and bendroflumethiazide 5 mg. May increase to 2 tablets daily if needed.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CORZIDE and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CORZIDE is classified as Category C. CORZIDE (nadolol/bendroflumethiazide) is associated with fetal risk. First trimester: Potential teratogenic effects including hypospadias and neural tube defects with bendroflumeth. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.